Table of Contents
What changed
Revenue fell 23.3% to NZ$690.6m (27% in constant currency) against an HY22 base that reflected peak pandemic hospital demand. Operating profit declined 58.1% to NZ$126.7m and profit before tax fell 62.0% to NZ$114.3m. NPAT declined a shallower 56.8% to NZ$95.9m because the effective tax rate dropped to 16.1% from 26.3% — so PBT is the cleaner operating read.
The mix rotated: Hospital revenue share fell from 74.4% to 63.5% while Homecare rose from 25.2% to 36.2%, consistent with the unwind of acute-care consumables demand. Operating cash flow collapsed to NZ$1.9m from NZ$127.5m, while capex stepped up to NZ$124.8m (18.1% of revenue) from NZ$81.3m (9.0%). Inventory rose 36.5% to NZ$398.4m, pushing inventory days to 104.9 from 59.0. Gross borrowings climbed to NZ$112.4m and cash fell to NZ$69.8m, flipping the group from net cash of NZ$30.9m to net debt of NZ$42.6m. The interim dividend was nudged up 2.9% to 17.5 cps.
What matters
- Earnings quality is weaker than the NPAT line suggests. The 5.3pp gap between PBT (-62.0%) and NPAT (-56.8%) reflects a one-off tax benefit, not operating improvement. ROE halved to 6.5% from 13.9%.
- Working capital and capex together absorbed the cash. Inventory days nearly doubled and capex intensity doubled, so operating cash converted at roughly 2% of NPAT this half. The company's own "free cash flow" metric of NZ$39.6m does not reconcile cleanly to OCF less capex in the supplied data, indicating a non-operating/working-capital swing worth scrutinising.
- Balance sheet has turned. A NZ$73.5m swing from net cash to net debt, combined with a dividend payout of 105.4% of NPAT (and 255.4% of the disclosed FCF measure), marks a clear step-down in balance-sheet flexibility even though absolute leverage remains low.
Expectations
No forward revenue or earnings target was provided in the release excerpts. Against the FY22 anchor (revenue NZ$1,681.7m, NPAT NZ$376.9m), simply annualising HY23 implies FY23 revenue of roughly NZ$1,381m — about 17.9% below FY22. Historically HY has been first-half-weighted (HY22 delivered 53.5% of FY22 revenue and 58.9% of NPAT), so a flat-run-rate extrapolation would if anything overstate the second half. Management references a 21% increase on pre-pandemic HY20 revenue (NZ$570.9m), which is the shape context the release itself offers. The release does not support any inference that H2 will re-accelerate beyond the current run-rate.
Quality of result
Low. The PBT decline tracks the revenue reset with clear operational deleverage, which is itself a durable feature rather than a one-off. But several items flatter or distort the reported figures: a 10.2pp fall in the effective tax rate cushioned NPAT; the company-defined free cash flow (NZ$39.6m) sits well above reported OCF minus capex (NZ$1.9m less NZ$124.8m), with the bridge not disclosed in the supplied excerpts; and cash conversion deteriorated materially. Inventory growth of NZ$106.6m year-on-year is a balance-sheet absorption of earnings that has yet to reverse. FX contributed roughly 4pp of benefit to reported revenue, so constant-currency declines are worse than headline.
Unresolved
- What drives the NZ$39.6m "free cash flow" figure when OCF was only NZ$1.9m and capex was NZ$124.8m? The reconciliation is not in the supplied data.
- Is the inventory build a deliberate hospital-hardware positioning decision, a demand miss, or a supply-chain hedge — and at what point does it begin to unwind into cash?
- Why was the effective tax rate 16.1%, and is that sustainable into H2 and FY24?
- With net debt now positive and the interim dividend exceeding NPAT, what is the medium-term payout policy if earnings do not recover quickly?
- Segment profitability was not disclosed, so the margin impact of the Hospital-to-Homecare mix shift cannot be assessed.
This briefing cannot assess forward demand trajectory, gross margin movement, or valuation, as none of those were disclosed in the supplied extraction.
Key metrics
| Metric | HY23 | HY22 | Change |
|---|---|---|---|
| Revenue | $690.6m | $900m | -23.3% ↓ |
| Net profit after tax | $95.9m | $221.8m | -56.8% ↓ |
| Net cash inflow from operating activities | $1900m | $127.5m | +1390.2% ↑ |
| Interim dividend per share | 17.5c | 17.0c | +2.9% ↑ |
| Operating profit | $126.7m | $302.4m | -58.1% ↓ |
| Profit before tax | $114.3m | $301.1m | -62.0% ↓ |
| Cash and cash equivalents | $69.8m | $103.2m | -32.4% ↓ |
| Total assets | $2094.5m | $2045.4m | +2.4% ↑ |
Reference: annolyse.ai/briefings/fph-hy23
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Hospital product group | $438.7m | $670m | — | -10.9pp |
| Homecare product group | $249.9m | $227m | — | +11.0pp |
Reference: annolyse.ai/briefings/fph-hy23
Analytical metrics
| Metric | HY23 | HY22 | Context |
|---|---|---|---|
| PBT growth | -62.0% | — | cleaner earnings measure |
| Effective tax rate | 16.1% | 26.3% | — |
| FCF pre-lease | $39.6m | −$129.6m | +$169.2m |
| FCF / NPAT | 41.3% | -58.4% | complementary conversion metric |
| Capex % revenue | 18.1% | 9.0% | — |
| Capex | $124.8m | −$81.3m | +$206.1m |
| Free cash flow | $39600.0m | $39.6m | +$39560.4m |
| Debtor days | 40.5 | 40.8 | -0.3 days |
| Inventory days | 104.9 | 59.0 | +45.9 days |
| Operating working capital | $552.2m | $493.5m | +$58.7m absorbed |
| Trade debtors | $153.8m | $201.7m | −$47.9m |
| Net debt | $42.6m | −$30.9m | +$73.5m |
| Gross borrowings | $112.4m | $72.3m | +$40.1m |
| Payout ratio vs NPAT | 105.4% | — | — |
| Payout ratio vs FCF pre-lease | 255.4% | — | not covered |
| ROE (annualised) | 6.5% | 13.9% | Weakening |
| HY22 share of FY22 revenue | 53.5% | — | Other half was 46.5% |
| HY22 share of FY22 NPAT | 58.9% | — | Other half was 41.1% |
| Profit from continuing operations | $95.9m | $221.8m | −$125.9m |
Reference: annolyse.ai/briefings/fph-hy23
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.